M. Hase

Efficacy of dimethyl fumarate in Japanese multiple sclerosis patients: interim analysis of randomized, double-blind APEX study and its open-label extension

T. Kondo, I. Kawachi, K. Hiramatsu, 2019, Multiple sclerosis journal - experimental, translational and clinical.

Efficacy and safety of dimethyl fumarate in treatment-naïve Japanese patients with multiple sclerosis: Interim analysis of the randomized placebo-controlled study

M. Mori, K. Hiramatsu, T. Ohashi, 2019, Multiple sclerosis journal - experimental, translational and clinical.

72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension

M. Niino, H. Ochi, K. Hiramatsu, 2018, Advances in Therapy.

Genetic variants in C5 and poor response to eculizumab.

J. Inazawa, K. Ando, Y. Kanakura, 2014, The New England journal of medicine.

Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan

K. Yokoyama, T. Saida, H. Makioka, 2017, Neurology and Therapy.

Insights on diagnosis and therapeutic decision-making patterns for multiple sclerosis treatment: cross-sectional opinion survey results from Japanese neurologists

H. Ochi, K. Hiramatsu, M. Hase, 2018, Multiple Sclerosis and Demyelinating Disorders.

Efficacy and safety of dimethyl fumarate in treatment-naïve Japanese patients with multiple sclerosis: Interim analysis of the randomized placebo-controlled study

M. Mori, K. Hiramatsu, T. Ohashi, 2019, Multiple sclerosis journal - experimental, translational and clinical.